Switching from Strattera (Atomoxetine) to Effexor (Venlafaxine)
When switching from atomoxetine to venlafaxine in adults, implement a cross-taper approach: gradually reduce atomoxetine while simultaneously initiating venlafaxine at 75 mg/day, allowing at least 5-7 days of overlap before fully discontinuing atomoxetine.
Switching Strategy
The most practical approach is a cross-taper method 1. This involves:
- Start venlafaxine XR at 75 mg/day while the patient is still on their current atomoxetine dose
- Overlap for 5-7 days to allow venlafaxine to begin engaging serotonin reuptake transporters (SERT), which occurs rapidly at this dose 2
- Gradually taper atomoxetine over 1-2 weeks while maintaining venlafaxine
- Titrate venlafaxine upward as needed after atomoxetine is discontinued
This strategy is superior to abrupt switching or prolonged washout periods, which risk symptom exacerbation during untreated intervals 3.
Pharmacological Rationale
These medications have complementary but distinct mechanisms that make cross-tapering safe:
- Atomoxetine primarily inhibits norepinephrine reuptake (NET) with minimal serotonin effects—only achieving ~40% SERT inhibition even at 80 mg/day 2
- Venlafaxine at 75 mg achieves ~60% SERT inhibition immediately but doesn't significantly engage NET until doses reach 225 mg/day 2
- No MAOI activity in either medication eliminates the need for extended washout periods 4
- No dangerous drug interactions between these two agents due to their different primary mechanisms
Dosing Considerations After Switch
Once atomoxetine is fully discontinued:
- For anxiety or depression: Venlafaxine 75-150 mg/day is often sufficient initially, as SERT inhibition is robust at these doses 4
- For dual noradrenergic effects: Consider titrating to 225 mg/day or higher, as NET inhibition only becomes clinically significant at this threshold 2
- Titration schedule: Increase by 75 mg weekly as tolerated, up to 225-375 mg/day maximum 4, 5
Critical Monitoring Points
Watch for discontinuation symptoms from atomoxetine, though these are generally less severe than with serotonergic agents. Common issues during the switch include:
- Increased side effects during overlap: dry mouth, sweating, orthostatic dizziness (occur in 15-29% of patients on venlafaxine) 5
- Most side effects peak early and diminish over 2-4 weeks even at higher doses 5
- Cardiovascular monitoring: Check blood pressure at each dose increase, particularly above 150 mg/day 4
Avoid These Pitfalls
- Don't use a prolonged washout period—this creates unnecessary treatment gaps and risks symptom worsening 3
- Don't start venlafaxine at doses above 75 mg initially—this increases side effect burden without additional early benefit 4
- Don't expect immediate noradrenergic effects from venlafaxine—if the patient specifically needs NET inhibition (as atomoxetine provided), you must reach 225 mg/day 2
- Don't abruptly stop atomoxetine—taper over 1-2 weeks to minimize withdrawal symptoms 3
When to Use This Switch
This switch is appropriate when:
- Atomoxetine provides inadequate response for ADHD or depression
- Patient requires serotonergic augmentation (depression, anxiety, panic disorder)
- Atomoxetine causes intolerable side effects
- Patient has comorbid depression or anxiety disorders where venlafaxine has superior evidence 4, 6
The cross-taper method with 5-7 day overlap represents the optimal balance between safety, tolerability, and maintaining therapeutic coverage throughout the transition 1, 3.